tbuckley/cabot-search huggingface dataset:
Delusions of parasitosis*
Authors: ALAN LYELL
Journal: British Journal of Dermatology (1983)

Journal Article Delusions of parasitosis Get access ALAN LYELL ALAN LYELL Craigallion, Skelmorlie, Ayrshire PA17 5DT, Scotland Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 108, Issue 4, 1 April 1983, Pages 485–499, https://doi.org/10.1111/j.1365-2133.1983.tb04604.x Published: 01 April 1983
Age distribution of amyloid in the intervertebral discs.
Authors: T Wagner, W Mohr
Journal: Annals of the Rheumatic Diseases (1984)

dermatomyositis was made.Apart from persistent telan- giectasia she completely recovered over the course of a year.Ten years later, having been completely fit in the interim, she again developed similar symptoms affecting the skin and proximal muscle groups.Muscle biopsy showed non-specific changes only in the sections ex- amined.Again without any drug therapy her symptoms resolved completely within a year.She remained completely well until June 1981 when she presented to the Rheumatology Department with a further recrudescence of dermatomyositis, confirmed on skin biopsy and with an associated elevation of muscle enzymes (CPK 1677 U/1, AST 78 U/1, HBD 495 U/l) and typical EMG findings supporting the diagnosis.In view of the severity of this attack and despite the self-limiting nature of previous attacks she was treated with steroids and azathioprine, and two years later remains well on prednisolone 5 mg daily and azathioprine 50 mg b.d.The prognosis of dermatomyositis is variable-about one third achieving complete remission or cure.Relapses, when they do occur, generally occur within a year of the initial attack.Recurrences separated by such long periods of remission are rare.Over the course of 34 years our patient has had three attacks of dermatomyositis, enjoying good health between attacks.
CD31 <sup>+</sup> Cells Represent Highly Angiogenic and Vasculogenic Cells in Bone Marrow
Authors: Hyongbum Kim, Hyun-Jai Cho, Sung-Whan Kim, Bianling Liu, Yong Jin Choi, JiYoon Lee, Young-Doug Sohn, Min-Young Lee, Mackenzie A. Houge, Young-sup Yoon
Journal: Circulation Research (2010)

Rationale: Bone marrow (BM) cells play an important role in physiological and therapeutic neovascularization. However, it remains unclear whether any specific uncultured BM cell populations have higher angiogenic and vasculogenic activities. Moreover, there has been controversy regarding the vasculogenic ability of BM cells. Objective: Preliminary flow cytometric analysis showed that CD31, traditionally a marker for endothelial cells, is expressed in certain nonendothelial BM mononuclear cells in both human and mouse. Based on the conserved CD31 expression in the axis of hematopoietic stem/progenitor cells (HSC/HPCs) to endothelial cells, we further sought to determine the comprehensive vasculogenic and angiogenic characteristics of human and mouse BM-derived CD31 + cells. Methods and Results: Flow cytometric analysis demonstrated that all CD31 + cells derived from BM were CD45 + and expressed markers for both HSC/HPCs and endothelial cells. Comprehensive gene expression analyses revealed that BM-CD31 + cells expressed higher levels of angiogenic genes than CD31 − cells. Endothelial progenitor cells, as well as HSC/HPCs, were almost exclusively confined to the CD31 + cell fraction, and culture of CD31 + cells under defined conditions gave rise to endothelial cells. Finally, injection of CD31 + cells into ischemic hindlimb repaired ischemia, increased expression of angiogenic and chemoattractive factors, and, in part, directly contributed to vasculogenesis, as demonstrated by both 3D confocal microscopy and flow cytometry. Conclusions: These data indicate that BM-CD31 + cells represent highly angiogenic and vasculogenic cells and can be a novel and highly promising source of cells for cell therapy to treat ischemic cardiovascular diseases.
Concealment of drugs in food and beverages in nursing homes: cross sectional study
Authors: ⊘yvind Kirkevold, Knut Engedal
Journal: BMJ (2004)

<h3>Abstract</h3> <b>Objective</b> To examine the practice of concealing drugs in patients9 foodstuff in nursing homes. <b>Design</b> Cross sectional study with data collected by structured interview. <b>Setting</b> All five health regions in Norway. <b>Participants</b> Professional carers of 1362 patients in 160 regular nursing home units and 564 patients in 90 special care units for people with dementia. <b>Main outcome measures</b> Frequency of concealment of drugs; who decided to conceal the drugs; how this practice was documented in the patients9 records; and what types of drugs were given this way. <b>Results</b> 11% of the patients in regular nursing home units and 17% of the patients in special care units for people with dementia received drugs mixed in their food or beverages at least once during seven days. In 95% of cases, drugs were routinely mixed in the food or beverages. The practice was documented in patients9 records in 40% (96/241) of cases. The covert administration of drugs was more often documented when the physician took the decision to hide the drugs in the patient9s foodstuff (57%; 27/47) than when the person who made the decision was unknown or not recorded (23%; 7/30). Patients who got drugs covertly more often received antiepileptics, antipsychotics, and anxiolytics compared with patients who were given their drugs openly. <b>Conclusions</b> The covert administration of drugs is common in Norwegian nursing homes. Routines for such practice are arbitrary, and the practice is poorly documented in the patients9 records.
Protective Role of Humanin on Bortezomib-Induced Bone Growth Impairment in Anticancer Treatment
Authors: Emma Eriksson, Malin Wickström, Lova Segerström Perup, John I. Johnsen, Staffan Eksborg, Per Kogner, Lars Sävendahl
Journal: JNCI Journal of the National Cancer Institute (2014)

BackgroundBortezomib is a proteasome inhibitor currently studied in clinical trials of childhood cancers. So far, no side effects on bone growth have been reported in treated children. However, bortezomib was recently found to induce apoptosis in growth plate chondrocytes and impair linear bone growth in treated mice. We hypothesize that [Gly14]-humanin (HNG), a 24-amino acid synthetic antiapoptotic peptide, can prevent bortezomib-induced bone growth impairment.
Response to: ‘The country of residence affects the phenotype of familial Mediterranean fever? Is it real or a selection bias?’ by Korkmaz
Authors: Erkan Demirkaya, Seza Ozen
Journal: Annals of the Rheumatic Diseases (2014)

In our recent study, we provide evidence on the effect of migration on disease phenotype for the patients with familial Mediterranean fever (FMF) by comparing large numbers of eastern Mediterranean patients who have migrated to different European countries. We confirmed that patients with an eastern Mediterranean ancestry display milder phenotypic manifestations in a western environment.1 We would like to answer some questions raised by the letter of Korkmaz C.2

The percentage of Turkish patients was indeed higher in group A, whereas the percentage of Jewish patients increased among group …
Improving Guideline Adherence
Authors: Maria Ansari, Michael G. Shlipak, Paul A. Heidenreich, Denise Van Ostaeyen, Elizabeth C. Pohl, Warren S. Browner, Barry M. Massie
Journal: Circulation (2003)

The dissemination of clinical practice guidelines often has not been accompanied by desired improvements in guideline adherence. This study evaluated interventions for implementing a new practice guideline advocating the use of beta-blockers for heart failure patients.This was a randomized controlled trial involving heart failure patients (n=169) with an ejection fraction < or =45% and no contraindications to beta-blockers. Patients' primary providers were randomized in a stratified design to 1 of 3 interventions: (1) control: provider education; (2) provider and patient notification: computerized provider reminders and patient letters advocating beta-blockers; and (3) nurse facilitator: supervised nurse to initiate and titrate beta-blockers. The primary outcome, the proportion of patients who were initiated or uptitrated and maintained on beta-blockers, analyzed by intention to treat, was achieved in 67% (36 of 54) of patients in the nurse facilitator group compared with 16% (10 of 64) in the provider/patient notification and 27% (14 of 51) in the control groups (P<0.001 for the comparisons between the nurse facilitator group and both other groups). The proportion of patients on target beta-blocker doses at the study end (median follow-up, 12 months) was also highest in the nurse facilitator group (43%) compared with the control (10%) and provider/patient notification groups (2%) (P<0.001). There were no differences in adverse events among groups.The use of a nurse facilitator was a successful approach for implementing a beta-blocker guideline in heart failure patients. The use of provider education, clinical reminders, and patient education was of limited value in this setting.
Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer
Authors: Firas L. T. Al-Ubaidi, Niklas Schultz, Olga Loseva, Lars Egevad, Torvald Granfors, Thomas Helleday
Journal: Clinical Cancer Research (2013)

Abstract Purpose: Neoadjuvant castration improves response to radiotherapy of prostate cancer. Here, we determine whether castration therapy impairs nonhomologous end-joining (NHEJ) repair of DNA double-strand breaks (DSB) by downregulating Ku70 protein expression. Experimental Design: Twenty patients with locally advanced prostate cancer were enrolled, and 6 to 12 needle core biopsy specimens were taken from the prostate of each patient before treatment. Bilateral orchidectomy was conducted in eight patients and 12 patients were treated with a GnRH agonist. After castration, two to four similar biopsies were obtained, and the levels of Ku70 and γ-H2AX foci were determined by immunofluorescence in verified cancer tissues. Results: We observed that the androgen receptor binds directly to Ku70 in prostate tissue. We also found a reduction of the Ku70 protein levels in the cell nuclei in 12 of 14 patients (P &amp;lt; 0.001) after castration. The reduction in Ku70 expression correlated significantly with decreased serum prostate-specific antigen (PSA) levels after castration, suggesting that androgen receptor activity regulates Ku70 protein levels in prostate cancer tissue. Furthermore, a significant correlation between the reductions of Ku70 after castration versus changes induced of castration of γ-H2AX foci could be seen implicating a functional linkage of decreased Ku70 levels and impaired DNA repair. Conclusions: Castration therapy results in decreased levels of the Ku70 protein in prostate cancer cells. Because the Ku70 protein is essential for the NHEJ repair of DSBs and its downregulation impairs DNA repair, this offers a possible explanation for the increased radiosensitivity of prostate cancer cells following castration. Clin Cancer Res; 19(6); 1547–56. ©2013 AACR.
Fasting and sport: an introduction
Authors: R J Maughan
Journal: British Journal of Sports Medicine (2010)

Most humans observe an overnight fast on a daily basis, and the human body copes well with short duration fasting. Periodic fasting is widely practised for cultural, religious or health reasons. Fasting may take many different forms. Prolonged restriction of food and fluid is harmful to health and performance, and it is often automatically assumed that intermittent fasting will lead to decrements in exercise performance. Athletes who choose to fast during training or competitions may therefore be at a disadvantage. The available evidence does not entirely support this view, but there is little or no information on the effects on elite athletes competing in challenging environments. Prolonged periods of training in the fasted state may not allow optimum adaptation of muscles and other tissues. Further research on a wide range of athletes with special nutrition needs is urgently required. In events where performance might be affected, other strategies to eliminate or minimise any effects must be sought.
Narrative Review: Statin-Related Myopathy
Authors: Tisha R. Joy
Journal: Annals of Internal Medicine (2009)

Statin-related myopathy is a clinically important cause of statin intolerance and discontinuation. The spectrum of statin-related myopathy ranges from common but clinically benign myalgia to rare but life-threatening rhabdomyolysis. Observational studies suggest that myalgia can occur in up to 10% of persons prescribed statins, whereas rhabdomyolysis continues to be rare. The mechanisms of statin-related myopathy are unclear. Options for managing statin myopathy include statin switching, particularly to fluvastatin or low-dose rosuvastatin; nondaily dosing regimens; nonstatin alternatives, such as ezetimibe and bile acid–binding resins; and coenzyme Q10 supplementation. Few of these strategies have high-quality evidence supporting them. Because statin-related myopathy will probably become more common with greater numbers of persons starting high-dose statin therapy and the increasing stringency of low-density lipoprotein cholesterol level targets, research to better identify patients at risk for statin myopathy and to evaluate management strategies for statin-related myopathy is warranted.
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
Authors: C Lukas, R Landewé, J Sieper, M Dougados, J Davis, J Braun, S van der Linden, D van der Heijde
Journal: Annals of the Rheumatic Diseases (2008)

Objectives: To develop a new index for disease activity in ankylosing spondylitis (ASDAS) that is truthful, discriminative and feasible, and includes domains/items that are considered relevant by patients and doctors. Methods: Eleven candidate variables covering six domains of disease activity, selected by ASAS experts in a Delphi exercise, were tested in a three-step approach, similar to the methodology used for the disease activity score in rheumatoid arthritis. Data on 708 patients included in ISSAS (International Study on Starting tumour necrosis factor blocking agents in Ankylosing Spondylitis) were used. Cross validation was carried out in the OASIS cohort (Outcome in Ankylosing Spondylitis International Study). Results: Principal component analysis disclosed three factors with eigenvalues &gt;0.75: patient assessments, peripheral joint assessments and acute phase reactants. Discriminant function analysis resulted in a correct classification in ∼72% of the cases (prior probability ∼50%). Regression analysis resulted in an index with five variables (total back pain, patient global assessment, duration of morning stiffness, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)). Three additional candidate indices were designed using similar methodology while omitting either ESR or CRP or patient global assessment. All four scores correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; r = 0.67–0.80), patient (0.58–0.75) and physician’s global assessment (0.41–0.48) of disease activity. All four candidate ASDAS indices performed better than BASDAI or single-item variables in discriminating between high and low disease activity state, according to doctors as well as patients in the OASIS cohort. Conclusion: The first steps in the development of a new assessment tool of disease activity in AS derived four candidate indices with good face and construct validity, and high discriminant capacity.
Renal Function Is Associated With Peak Exercise Capacity in Adolescents With Type 1 Diabetes
Authors: Petter Bjornstad, Melanie Cree-Green, Amy Baumgartner, David M. Maahs, David Z. Cherney, Laura Pyle, Judith G. Regensteiner, Jane E. Reusch, Kristen J. Nadeau
Journal: Diabetes Care (2014)

OBJECTIVE Diabetic nephropathy and cardiovascular disease are strongly related in adults with type 1 diabetes, yet little is known about this relationship in adolescents prior to the onset of detectable clinical disease. We hypothesized that cardiopulmonary fitness would be directly associated with albumin-to-creatinine ratio (ACR) and inversely related to estimated glomerular filtration rate (eGFR) in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS Sixty-nine adolescents with type 1 diabetes and 13 nondiabetic control subjects of similar pubertal stage and BMI had insulin sensitivity (glucose infusion rate [GIR]), measured by hyperinsulinemic-euglycemic clamp, and lean body mass, measured by DEXA. Cardiopulmonary fitness was measured by cycle ergometry to obtain peak volume of oxygen (VO2peak), and renal function was measured by eGFR using the Bouvet equation (measuring creatinine and cystatin C levels) and ACR. RESULTS Adolescents (15.5 ± 2.2 years of age) with type 1 diabetes (6.3 ± 3.8 years diabetes duration) had reduced VO2peak (31.5 ± 6.3 vs. 36.2 ± 7.9 mL/kg ⋅ min, P = 0.046) and VO2peak/lean kg (43.7 ± 7.0 vs. 51.0 ± 8.6 mL/lean kg ⋅ min, P = 0.007) compared with nondiabetic control subjects. eGFR was inversely associated with VO2peak and VO2peak/lean kg after adjusting for sex, Tanner stage, GIR, HbA1c level, systolic blood pressure, and LDL cholesterol level (β ± SE, VO2peak: −0.19 ± 0.07, P = 0.02; VO2peak/lean kg: −0.19 ± 0.09, P = 0.048). Moreover, participants in the highest tertile for eGFR had significantly lower sex- and Tanner-adjusted VO2peak and VO2peak/lean kg compared with participants in the lowest tertile. CONCLUSIONS Adolescents with type 1 diabetes had reduced exercise capacity, which was strongly associated with renal health, independent of insulin sensitivity. Future studies should examine the underlying interrelated pathophysiology in order to identify probable targets for treatment to reduce cardiovascular and renal complications.
A. C. E. Mixture
Authors: J. Walters
Journal: BMJ (1887)

F.ourthly, when;two deaths from small-pok, itt the short space of a fortnight, take place in such a place as the Perth Infirmary, the Medical Officer of Health surely cannot be called a" panic-stricken " party -when he draws attention to it.Fifthly, as the Infirmary medical staff are revaccinating in one spot, your criticism on this point may not appear amiss.If, therefore, you have received a "one-sided account," you may possibly be able to amend it from the above.-Iam, etc.,
Pregnancy and child outcome after oocyte donation
Authors: V. Soderstrom Anttila
Journal: Human Reproduction Update (2001)

During the last decade oocyte donation has been highly successful for treating women previously thought to be hopelessly infertile. The pregnancy rate after oocyte donation is among the highest reported for any fertility-enhancing procedure. Most investigators have noted an increased rate of obstetric complications in these pregnancies. In particular, pregnancy-induced hypertension appears to occur more often than expected, and the Caesarean section rate is high. However, the majority of oocyte recipients experience a favourable pregnancy and perinatal outcome. When perinatal complications occur they are usually related to multiple gestation. The high frequency of multiple pregnancy after oocyte donation, as well as in all other fields of assisted reproduction, deserves attention, and efforts to avoid multi-fetal gestation must be made. There are only a few studies on post-natal growth and development of young children born after oocyte donation. The health of these children appears to be within normal ranges. The psychological consequences of the treatment on the child require further investigation. Thus far, studies have shown normal socio–emotional development in the child and a warm relationship between the parents and the child in oocyte donation families.
A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays
Authors: Elisabetta Marangoni, Anne Vincent-Salomon, Nathalie Auger, Armelle Degeorges, Franck Assayag, Patricia de Cremoux, Ludmilla de Plater, Charlotte Guyader, Gonzague De Pinieux, Jean-Gabriel Judde, Magali Rebucci, Carine Tran-Perennou, Xavier Sastre-Garau, Brigitte Sigal-Zafrani, Olivier Delattre, Véronique Diéras, Marie-France Poupon
Journal: Clinical Cancer Research (2007)

Abstract Purpose: To establish a panel of human breast cancer (HBC) xenografts in immunodeficient mice suitable for pharmacologic preclinical assays. Experimental Design: 200 samples of HBCs were grafted into Swiss nude mice. Twenty-five transplantable xenografts were established (12.5%). Their characterization included histology, p53 status, genetic analysis by array comparative genomic hybridization, gene expression by Western blotting, and quantitative reverse transcription-PCR. Biological profiles of nine xenografts were compared with those of the corresponding patient's tumor. Chemosensitivities of 17 xenografts to a combination of Adriamycin and cyclophosphamide (AC), docetaxel, trastuzumab, and Degarelix were evaluated. Results: Almost all patient tumors established as xenografts displayed an aggressive phenotype, i.e., high-grade, triple-negative status. The histology of the xenografts recapitulated the features of the original tumors. Mutation of p53 and inactivation of Rb and PTEN proteins were found in 83%, 30%, and 42% of HBC xenografts, respectively. Two HBCx had an ERBB2 (HER2) amplification. Large variations were observed in the expression of HER family receptors and in genomic profiles. Genomic alterations were close to those of original samples in paired tumors. Three xenografts formed lung metastases. A total of 15 of the 17 HBCx (88%) responded to AC, and 8 (47%) responded to docetaxel. One ERBB2-amplified xenograft responded to trastuzumab, whereas the other did not. The drug response of HBC xenografts was concordant with that of the patient's tumor in five of seven analyzable cases. Conclusions: This panel of breast cancer xenografts includes 15 triple-negative, one ER positive and 2 ERBB2 positive. This panel represents a useful preclinical tool for testing new agents and protocols and for further exploration of the biological basis of drug responses.